Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
CYTALUX (Pafolacianine) Injection: early-phase trial registry
1 of 1 indexed CYTALUX (Pafolacianine) Injection trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #11,370 of 28,707 conditions by registered trial count.
1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count
CYTALUX (Pafolacianine) Injection: 1 US clinical trial tracked, 1 recruiting.
CYTALUX (Pafolacianine) Injection is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Abramson Cancer Center at Penn Medicine, running 1 of these trials.
Enrollment posture brief
Registry condition cytalux-pafolacianine-injection
OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
CYTALUX (Pafolacianine) Injection lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for CYTALUX (Pafolacianine) Injection on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
CYTALUX (Pafolacianine) Injection is recruiting above its size-band peers.
1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on CYTALUX (Pafolacianine) Injection records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on CYTALUX (Pafolacianine) Injection trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this CYTALUX (Pafolacianine) Injection page
1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 CYTALUX (Pafolacianine) Injection trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Abramson Cancer Center at Penn Medicine sponsors the most CYTALUX (Pafolacianine) Injection trials on record, review their full trial history before evaluating a specific study. See Abramson Cancer Center at Penn Medicine's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This CYTALUX (Pafolacianine) Injection condition card totals 1 registered trials; most-linked intervention 1788 4K Camera System with Advanced Imaging Modality; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.